title: Commentary: bevacizumab and erlotinib with chemoradiation for head and neck cancer.
authors.affiliation: Department of Medical Oncology and the Developmental Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA, USA. barbara.burtness@fccc.edu
authors.forename: Barbara
authors.initials: B
authors.lastname: Burtness
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000532:radiotherapy*; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D006801:Humans; D008297:Male